hVIVO plc operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America. It provides end-to-end early clinical development services to the biopharmaceutical industry, including phase I capabilities and world leading human challenge trial…more
hVIVO plc operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America. It provides end-to-end early clinical development services to the biopharmaceutical industry, including phase I capabilities and world leading human challenge trial…more
Analyst consensus: Buy
As of 12 Aug 2026, 8 analysts rate hVIVO plc a Buy, with 75% buy ratings and a mean price target of 17p (range 10p–29p), +151% vs the current price.